Aprea Therapeutics’ (APRE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Aprea Therapeutics Price Performance

Shares of APRE opened at $3.34 on Tuesday. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $8.85. The stock has a market cap of $18.15 million, a PE ratio of -1.19 and a beta of 0.88. The firm has a fifty day moving average price of $3.44 and a 200 day moving average price of $3.57.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. The business had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. As a group, equities analysts expect that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling at Aprea Therapeutics

In other news, Director Marc Duey sold 6,462 shares of Aprea Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the transaction, the director now directly owns 233,651 shares of the company’s stock, valued at $1,070,121.58. The trade was a 2.69 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bernd R. Seizinger purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The shares were acquired at an average price of $2.68 per share, with a total value of $26,800.00. Following the purchase, the director now owns 44,730 shares in the company, valued at $119,876.40. This trade represents a 28.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 42,290 shares of company stock worth $165,096. 12.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is currently owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.